Navigation Links
Genesis Biopharma Announces Termination of Previously Announced Proposed Public Offering
Date:5/7/2012

LOS ANGELES, May 7, 2012 /PRNewswire/ -- Genesis Biopharma, Inc. (OTCBB: GNBP), a biotechnology company developing targeted cancer immunotherapies, announced today that it is terminating its previously announced proposed public offering pursuant to a preliminary prospectus supplement and an effective shelf registration statement on file with the Securities and Exchange Commission due to market conditions. 

"The Company intends to pursue alternative financing under more favorable conditions", stated Anthony Cataldo, President & Chief Executive Officer of Genesis Biopharma, Inc. 

About Genesis Biopharma, Inc.

Genesis Biopharma, Inc. is engaged in the development and commercialization of autologous cell therapies for the treatment of various cancers.  The company's lead product candidate, Contego™, is a ready-to-infuse autologous cell therapy utilizing tumor infiltrating lymphocytes for the treatment of patients with Stage IV metastatic melanoma.  Contego™ is based on a currently available physician-sponsored investigational therapy at the National Cancer Institute, MD Anderson Cancer Center and the H. Lee Moffitt Cancer & Research Institute for the treatment of Stage IV metastatic melanoma. 

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks detailed from time to time in the company's filings with the Securities and Exchange Commission, and represent the company's views only as of the date they are made and should not be relied upon as representing the company's views as of any subsequent date.  The company does not assume any obligation to update any forward-looking statements.


'/>"/>
SOURCE Genesis Biopharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. ThermoGenesis Corp. To Announce Third Quarter Fiscal 2012 Results On May 10, 2012
2. ThermoGenesis Announces AABB Accreditation for Cord Blood Products Customer in China
3. ThermoGenesis Announces Webcast of Presentation at Roth Capital Conference
4. ThermoGenesis Reports Second Quarter Fiscal 2012 Results
5. Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others
6. ThermoGenesis Provides Update on Res-Q® Clinical Evaluations at Leading Stem Cell Therapy Conference
7. Canadas First National Public Cord Blood Bank Adopts ThermoGenesis BioArchive Cryopreservation System
8. Thermogenesis Signs Worldwide Res-Q System Distribution Agreement With Arthrex for Sports Medicine Applications
9. ThermoGenesis Announces Webcast of Presentation at OneMedForum Conference
10. Genesis Biopharmas Scientific and Medical Advisory Board Welcomes Dr. Steven A. Rosenberg, Chief of the Surgery Branch at the NCI
11. Triple Analysis: Prostate Cancer, Angiogenesis and Peptides
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... 2015  XRpro Sciences, Inc., a provider of a unique ... throughput transporter and ion channel assays for the pharmaceutical industry, ... 2015 Marcum MicroCap Conference on Thursday, May 28, 2015 ... Grand Hyatt Hotel. The Company,s presentation by ... is scheduled to begin at 1:30 p.m ET. Click here ...
(Date:5/26/2015)...  Amgen (NASDAQ: AMGN ) today announced the ... study in the Journal of Clinical Oncology ... JCO , which were previously presented at the ... (ASCO) in 2013 and 2014, demonstrated a significantly higher ... IIIB, IIIC or IV metastatic melanoma receiving the investigational ...
(Date:5/26/2015)... HERTFORDSHIRE , England and PITTSBURGH , ... ), a leading global pharmaceutical company, today announced that ... at the Bernstein Strategic Decisions Conference, Friday, May 29, ... parties can access a live webcast of the presentation ... http://mylan.com/investors . An archived version will also be ...
Breaking Medicine Technology:XRpro Sciences, Inc. To Present at 2015 Marcum MicroCap Conference 2Pivotal Study Results Published in Journal of Clinical Oncology Showed Talimogene Laherparepvec Improved Durable Response Rates in Patients With Metastatic Melanoma 2Pivotal Study Results Published in Journal of Clinical Oncology Showed Talimogene Laherparepvec Improved Durable Response Rates in Patients With Metastatic Melanoma 3Pivotal Study Results Published in Journal of Clinical Oncology Showed Talimogene Laherparepvec Improved Durable Response Rates in Patients With Metastatic Melanoma 4Pivotal Study Results Published in Journal of Clinical Oncology Showed Talimogene Laherparepvec Improved Durable Response Rates in Patients With Metastatic Melanoma 5Pivotal Study Results Published in Journal of Clinical Oncology Showed Talimogene Laherparepvec Improved Durable Response Rates in Patients With Metastatic Melanoma 6Pivotal Study Results Published in Journal of Clinical Oncology Showed Talimogene Laherparepvec Improved Durable Response Rates in Patients With Metastatic Melanoma 7Pivotal Study Results Published in Journal of Clinical Oncology Showed Talimogene Laherparepvec Improved Durable Response Rates in Patients With Metastatic Melanoma 8
... paroxetine produced no significant drug interaction,with paliperidone ... -- After administration of,paliperidone extended-release (ER) tablets, ... when given with a common antidepressant,according to ... Annual Meeting,of the American Psychiatric Association. Paroxetine, ...
... Spain, May 23, 2007 /PRNewswire-FirstCall/ -- ... recently completed animal,study, a DNA vaccine ... and delivered by needle-free injection,yielded significantly ... vaccine delivered by needle and syringe. ...
Cached Medicine Technology:Blood Levels of Paliperidone Extended-Release Tablets are Not,Increased by Common Antidepressant 2Blood Levels of Paliperidone Extended-Release Tablets are Not,Increased by Common Antidepressant 3Blood Levels of Paliperidone Extended-Release Tablets are Not,Increased by Common Antidepressant 4Blood Levels of Paliperidone Extended-Release Tablets are Not,Increased by Common Antidepressant 5Blood Levels of Paliperidone Extended-Release Tablets are Not,Increased by Common Antidepressant 6Vical's Vaxfectin Adjuvant With Needle-free Delivery Enhances DNA,Vaccine Performance; Yields Antibody Responses Comparable to,Electroporation Without Tolerability Issues 2Vical's Vaxfectin Adjuvant With Needle-free Delivery Enhances DNA,Vaccine Performance; Yields Antibody Responses Comparable to,Electroporation Without Tolerability Issues 3Vical's Vaxfectin Adjuvant With Needle-free Delivery Enhances DNA,Vaccine Performance; Yields Antibody Responses Comparable to,Electroporation Without Tolerability Issues 4
(Date:5/27/2015)... (PRWEB) May 27, 2015 Get ... dedicated to ending the spread of HIV, will recognize ... the 1st Annual YesGTCV Social Ambassador Awards, to be ... 7 p.m. PST. , A first for public health ... Coachella Valley’s most active online influencers for breaking down ...
(Date:5/27/2015)... Ca (PRWEB) May 27, 2015 According ... of Texas Southwestern Medical Center at Dallas some migraine ... syndrome. Both CTS and migraine headache apparently also have ... in incidents of obesity, people with a history of ... less common in Asians, and CTS in particular was ...
(Date:5/27/2015)... The Advanced Fertility Center of Chicago announces that their ... better serve the needs of couples in Chicagoland. The ... Northwest side of the city at 4920 North Central Ave., ... the Chicago office at (773) 794–1818. This is the ... The other 2 offices are in Gurnee and Crystal ...
(Date:5/26/2015)... Missouri (PRWEB) May 27, 2015 ... recently filed testosterone gel lawsuit . The suit ... AbbVie. The suit was filed in late April 2015, ... filed in an Illinois federal court in mid-May.¹ , ... District Court for the Northern District of Illinois. The ...
(Date:5/26/2015)... 27, 2015 Securityhunter has ... by the United States Department of Health and Human ... The MATOC was awarded through the General Services ... for the PSC, which is a fee-for-service agency. The ... year options, and is an enterprise–wide physical security and ...
Breaking Medicine News(10 mins):Health News:Regional Public Health Campaign to Host 1st Annual YesGTCV Social Ambassador Awards 2Health News:Regional Public Health Campaign to Host 1st Annual YesGTCV Social Ambassador Awards 3Health News:Santa Rosa Orthopaedics Offers Insights into Recent Study Results Connecting Migraines with Chronic Conditions Such as Carpal Tunnel Syndrome 2Health News:Santa Rosa Orthopaedics Offers Insights into Recent Study Results Connecting Migraines with Chronic Conditions Such as Carpal Tunnel Syndrome 3Health News:Santa Rosa Orthopaedics Offers Insights into Recent Study Results Connecting Migraines with Chronic Conditions Such as Carpal Tunnel Syndrome 4Health News:The Advanced Fertility Center of Chicago Opens a New Fertility Office Location in Chicago 2Health News:Carey Danis & Lowe Comments on Recently Filed Testosterone Gel Lawsuit 2Health News:Securityhunter Has Been Awarded a Multiple Award Task Order Contract (MATOC) by the Department of Health and Human Services 2
... odds are still low and headache sufferers shouldn,t worry, researcher ... more common in women with multiple sclerosis (MS) than in ... looked at close to 117,000 U.S. women participating in the ... with migraine at the start of the study. The women ...
... life in first year,s aftermath impacted by lack of social ... in greater need of social support in the critical year ... The study of 2,411 people treated for heart attacks at ... who received the least support from health personnel, families and ...
... ... Desmond- Hellmann for a town hall meeting with UCSF faculty, staff, and students. , ... San Francisco, CA (PRWEB) February 16, ... town hall meeting with UCSF faculty, staff, and students. , , , , ,The Senator ...
... , Prominent Georgia Physicians ... Seniors, Military Families , WASHINGTON , Feb. 16 ... Johnny Isakson , two prominent Georgia physicians who head ... James Rohack , M.D. to call for Senate action this month to ...
... researchers have developed a hands-free alternative to cell phone texting ... it, make it safer," said Juan Gilbert, professor and chairman ... He said one problem with banning texting while driving ... said it will be difficult for police to can,t enforce ...
... ... universities and students , ... Tenn. (Vocus) February 16, 2010 -- PureSafety , a leading provider of results-driven software ... publication for environmental, health and safety (EHS) professionals, today announced the launch of Future ...
Cached Medicine News:Health News:Migraine Tied to Raised Multiple Sclerosis Risk 2Health News:Women Need More Help After Heart Attack 2Health News:Women Need More Help After Heart Attack 3Health News:Women Need More Help After Heart Attack 4Health News:Sen. Arlen Specter to Address Town Hall at UCSF Today 2Health News:Georgia Senators Urged to Stop Medicare Cut Before March 1 Deadline 2Health News:Georgia Senators Urged to Stop Medicare Cut Before March 1 Deadline 3Health News:PureSafety and EHS Today Launch Future Leaders in EHS 2Health News:PureSafety and EHS Today Launch Future Leaders in EHS 3
... The High Throughput Sorter RSD ... high volume laboratories in the field ... is not only of considerable speed ... optional Recapping Module can be integrated. ...
... System RCS 800 closes various plastic primary and ... way. Different tube heights and diameters can be ... be used for send-outs. The integration into other ... System RSD 800 and High Throughput Sorter RSD ...
... Decapping System DS 800 selectively removes closures from ... the barcode towards the rack opening in one ... integrated in PVT Systems like Sorting System RS ... Sorter RSD ProVolume and Aliquoting System RSD 800A. ...
... Nanogen offers reagents to detect sequences ... parainfluenza virus 1, 2 and 3; ... respiratory syncytial virus A and B. ... to create homebrew tests., ...
Medicine Products: